Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
- COVID-19
Apr 5, 2021
GSK to support manufacture of Novavax' COVID-19 vaccine
- COVID-19
Mar 29, 2021
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
- COVID-19
Mar 11, 2021
Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
- Corporate and Finance
Mar 8, 2021
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
- Corporate and Finance
Mar 1, 2021
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
- COVID-19
Feb 26, 2021
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
- COVID-19
Feb 22, 2021
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
- COVID-19
Feb 18, 2021
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
- Corporate and Finance
Feb 16, 2021
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
- COVID-19
Feb 15, 2021

Show per page